Open-Label CDCA 250 mg TID ( DrugBank: CDCA )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 263 | Cerebrotendinous xanthomatosis | 1 |
263. Cerebrotendinous xanthomatosis
Clinical trials : 6 / Drugs : 11 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 4
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04270682 (ClinicalTrials.gov) | January 31, 2020 | 12/2/2020 | Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) | A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis | CTX | Drug: Blinded CDCA 250 mg TID;Drug: Placebo;Drug: Open-Label CDCA 250 mg TID;Drug: Rescue Medication CDCA 250 mg TID;Drug: CDCA Weight-Based Dose TID | Travere Therapeutics, Inc. | NULL | Recruiting | 1 Month | N/A | All | 12 | Phase 3 | United States;Brazil |